{{Drugbox
| IUPAC_name = methyl (2''S'')-2-{[1-(cyclohexylmethyl)indazole-3-carbonyl]amino}-3-methylbutanoate
| image = AMB-CHMINACA.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = ([[racemate]])
| CAS_number = 1863066-03-8
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 119026010
| ChemSpiderID      = 32055578
| UNII = OU56JJP891
| smiles            = COC([C@H](C(C)C)NC(C1=NN(C2=C1C=CC=C2)CC3CCCCC3)=O)=O
| StdInChI          = 1S/C21H29N3O3/c1-14(2)18(21(26)27-3)22-20(25)19-16-11-7-8-12-17(16)24(23-19)13-15-9-5-4-6-10-15/h7-8,11-12,14-15,18H,4-6,9-10,13H2,1-3H3,(H,22,25)/t18-/m0/s1
| StdInChIKey       = CRGGXDSTBHQLKJ-SFHVURJKSA-N

<!--Chemical data-->
| C=21 | H=29 | N=3 | O=3
| molecular_weight = 371.5 g/mol
}}

'''AMB-CHMINACA''' (also known as '''MA-CHMINACA''') is an [[indazole]]-based [[synthetic cannabinoid]]<ref>{{cite journal|last1=Akamatsu|first1=Shigeki|last2=Yoshida|first2=Masashi|title=Fragmentation of synthetic cannabinoids with an isopropyl group or a tert-butyl group ionized by electron impact and electrospray|journal=Journal of Mass Spectrometry|date=January 2016|volume=51|issue=1|pages=28–32|doi=10.1002/jms.3722}}</ref> that is a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/16421 | title=MA-CHMINACA  | publisher=Cayman Chemical | accessdate=21 July 2015}}</ref><ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1301 | title=MA-CHMINACA | publisher=Southern Association of Forensic Scientists | accessdate=21 July 2015}}</ref><ref>{{cite journal | author1=Samuel D Banister et al. | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00112 | title=The pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues | date=July 2016 | journal=ACS Chemical Neuroscience | doi=10.1021/acschemneuro.6b00137 | pmid=27421060 | volume=7 | pages=1241–54}}</ref>

== Legal status==
AMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=21 July 2015}}</ref>

== See also ==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-CHFUPYCA]]
* [[AB-FUBINACA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADSB-FUB-187]]
* [[AMB-FUBINACA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[MDMB-CHMINACA]]
* [[MDMB-FUBINACA]]
* [[PX-2]]
* [[PX-3]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazoles]]
[[Category:Indazolecarboxamides]]


{{cannabinoid-stub}}